Q2 Earnings Estimate for ELEV Issued By William Blair

Elevation Oncology, Inc. (NASDAQ:ELEV) – Research analysts at William Blair issued their Q2 2025 earnings estimates for Elevation Oncology in a report issued on Friday, March 7th. William Blair analyst A. Hsieh expects that the company will post earnings of ($0.21) per share for the quarter. William Blair has a “Outperform” rating and a $5.00 price objective on the stock. The consensus estimate for Elevation Oncology’s current full-year earnings is ($0.84) per share. William Blair also issued estimates for Elevation Oncology’s Q3 2025 earnings at ($0.21) EPS and Q4 2025 earnings at ($0.24) EPS.

Elevation Oncology (NASDAQ:ELEV) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04.

A number of other analysts have also issued reports on ELEV. Stephens reissued an “overweight” rating and set a $5.00 target price on shares of Elevation Oncology in a research note on Friday, March 7th. JMP Securities reissued a “market outperform” rating and set a $7.00 target price on shares of Elevation Oncology in a research note on Thursday, December 19th. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of Elevation Oncology in a research note on Monday. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $6.83.

Elevation Oncology Stock Up 5.0 %

NASDAQ ELEV opened at $0.49 on Monday. The company has a quick ratio of 17.77, a current ratio of 17.77 and a debt-to-equity ratio of 0.45. The company has a fifty day moving average of $0.63 and a two-hundred day moving average of $0.62. The firm has a market capitalization of $29.26 million, a price-to-earnings ratio of -0.60 and a beta of 1.37. Elevation Oncology has a 52 week low of $0.41 and a 52 week high of $5.83.

Institutional Trading of Elevation Oncology

Several institutional investors and hedge funds have recently made changes to their positions in the company. Barclays PLC raised its holdings in shares of Elevation Oncology by 21.5% in the fourth quarter. Barclays PLC now owns 87,608 shares of the company’s stock valued at $49,000 after acquiring an additional 15,531 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Elevation Oncology by 33.9% in the fourth quarter. SG Americas Securities LLC now owns 61,467 shares of the company’s stock valued at $35,000 after acquiring an additional 15,560 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Elevation Oncology by 42.5% in the fourth quarter. Bank of America Corp DE now owns 56,839 shares of the company’s stock valued at $32,000 after acquiring an additional 16,962 shares in the last quarter. Two Sigma Advisers LP raised its holdings in shares of Elevation Oncology by 47.8% in the fourth quarter. Two Sigma Advisers LP now owns 84,400 shares of the company’s stock valued at $47,000 after acquiring an additional 27,300 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of Elevation Oncology by 3.9% in the fourth quarter. Millennium Management LLC now owns 815,916 shares of the company’s stock valued at $459,000 after acquiring an additional 30,466 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.

About Elevation Oncology

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.